A number of studies have suggested that the deactivation of EIF2AK2 can suppress tumor growth [31,32,33], while elevated expression of EIF2AK2 increases carcinoma progression in a variety of human cancer, including breast cancer [34,35,36]. This evidence concerns the gene EIF2AK2 and carcinoma.